MedPath
TGA Approval

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets blister pack (365510)

365510

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets blister pack

Gilead Sciences Pty Ltd

August 2, 2021

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/77d426f88e481f76f88bb376ae4a6c61.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/346743f14299ebc769fec95526a7ae35.pdf

Active Ingredients

bictegravir sodium

emtricitabine

tenofovir alafenamide fumarate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets blister pack (365510) - TGA 批准文号 | MedPath